Extended Long-Term Safety Study of KW-6500

NCT01063621 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

27

Enrollment

INDUSTRY

Sponsor class

Conditions

Parkinson's Disease

Interventions

DRUG: KW-6500

Sponsor

Kyowa Kirin Co., Ltd.